Title:
ANTAGONISTIC SMALL MOLECULE COMPOUND HAVING TOLL-LIKE RECEPTOR 7/9 INHIBITORY FUNCTION
Document Type and Number:
WIPO Patent Application WO/2021/225365
Kind Code:
A1
Abstract:
The present invention relates to an antagonistic small molecule compound having a Toll-like receptor (TLR) 7/9 inhibitory function and, more specifically, to a novel small molecule compound for inhibiting a TLR7/9 signaling path, a method for producing same, and a composition for preventing or treating an autoimmune disease or an inflammatory disease, comprising same. The novel compound according to the present invention not only blocks secretion of TNF-α induced by CpG-ODN (TLR9 agonist) or IMQ (TLR7 agonist) but also inhibits generation of inflammatory cytokines and, thus, is useful for prevention or treatment of TLR7/9-related autoimmune diseases and inflammatory diseases including systemic lupus erythematosus and psoriasis, in particular.
Inventors:
CHOI SANGDUN (KR)
RYU HYUNG CHUL (KR)
KIM JAE-SUN (KR)
RYU HYUNG CHUL (KR)
KIM JAE-SUN (KR)
Application Number:
PCT/KR2021/005624
Publication Date:
November 11, 2021
Filing Date:
May 04, 2021
Export Citation:
Assignee:
UNIV AJOU IND ACADEMIC COOP FOUND (KR)
International Classes:
C07D471/04; A61K31/437; A61P29/00; A61P37/00
Domestic Patent References:
| WO2020016243A1 | 2020-01-23 | |||
| WO2018134254A1 | 2018-07-26 |
Foreign References:
| US20090143352A1 | 2009-06-04 | |||
| KR101746199B1 | 2017-06-13 |
Other References:
HUANG ZHIHONG, TREMBLAY MATTHEW S., WU TOM Y.-H., DING QIANG, HAO XUESHI, BAATEN JANINE, HILL ROBERT, LIU BO, MEEUSEN SHELLY, ZOU : "Discovery of 5-(3,4-Difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-Cell Survival in Type 1 Diabetes", ACS OMEGA, vol. 4, no. 2, 28 February 2019 (2019-02-28), US, pages 3571 - 3581, XP055864111, ISSN: 2470-1343, DOI: 10.1021/acsomega.8b03050
TAKEUCHI, O. ET AL., J. IMMUNOL., vol. 169, 2002, pages 10 - 14
TAKEUCHI, O. ET AL., INT. IMMUNOL, vol. 13, 2001, pages 933 - 940
POLTORAK, A. ET AL., SCIENCE, vol. 282, 1998, pages 2085 - 2088
DIEBOLD, S. S. ET AL., SCIENCE, vol. 303, 2004, pages 1526 - 1529
HEMMI, H. ET AL., NATURE, vol. 408, 2000, pages 740 - 745
HEMMI, H. ET AL., NAT. IMMUNOL., vol. 3, 2002, pages 196 - 200
DEMARIA, O. ET AL., J. CLIN. INVEST, vol. 120, 2010, pages 3651 - 3662
VINCENT, FB ET AL., NAT. REV. RHEUMATOL., vol. 10, 2014, pages 365 - 373
KRIEG, A. M.VOLLMER, J, IMMUNOL. REV, vol. 220, 2007, pages 251 - 269
TERHORST, D ET AL., J. IMMUNOL, vol. 195, 2015, pages 4953 - 4961
TAKEUCHI, O. ET AL., J. IMMUNOL., vol. 169, 2002, pages 10 - 14
TAKEUCHI, O. ET AL., INT. IMMUNOL, vol. 13, 2001, pages 933 - 940
POLTORAK, A. ET AL., SCIENCE, vol. 282, 1998, pages 2085 - 2088
DIEBOLD, S. S. ET AL., SCIENCE, vol. 303, 2004, pages 1526 - 1529
HEMMI, H. ET AL., NATURE, vol. 408, 2000, pages 740 - 745
HEMMI, H. ET AL., NAT. IMMUNOL., vol. 3, 2002, pages 196 - 200
DEMARIA, O. ET AL., J. CLIN. INVEST, vol. 120, 2010, pages 3651 - 3662
VINCENT, FB ET AL., NAT. REV. RHEUMATOL., vol. 10, 2014, pages 365 - 373
KRIEG, A. M.VOLLMER, J, IMMUNOL. REV, vol. 220, 2007, pages 251 - 269
TERHORST, D ET AL., J. IMMUNOL, vol. 195, 2015, pages 4953 - 4961
Attorney, Agent or Firm:
LEE, Cheo Young et al. (KR)
Download PDF: